Is Bliss GVS Pharma overvalued or undervalued?

Jun 25 2025 09:40 AM IST
share
Share Via
As of June 24, 2025, Bliss GVS Pharma is considered undervalued with a PE ratio of 18.50 and an attractive valuation compared to peers like Sun Pharma and Cipla, supported by a strong 1-year stock return of 42.31% versus the Sensex's 6.10%.
As of 24 June 2025, Bliss GVS Pharma's valuation grade has moved from fair to attractive, indicating a shift towards being undervalued. The company currently has a PE ratio of 18.50, an EV to EBITDA of 11.32, and a Price to Book Value of 1.48, which are competitive compared to its peers. Notably, Sun Pharma has a significantly higher PE ratio of 34.85 and an EV to EBITDA of 24.61, while Cipla, which is also rated attractive, has a PE of 23.03 and an EV to EBITDA of 15.96.

Given these metrics, Bliss GVS Pharma appears to be undervalued relative to its peers in the pharmaceuticals and biotechnology sector. The company's recent stock performance has outpaced the Sensex, with a 1-year return of 42.31% compared to the Sensex's 6.10%, reinforcing the attractiveness of its current valuation.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News